DURHAM, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., Chief Executive Officer of Chimerix and Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix will participate in a fireside chat at the Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017 at 11:45 a.m. ET at the Lotte New York Palace Hotel in New York City.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About ChimerixChimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, for the treatment and prevention of norovirus.  For further information, please visit Chimerix's website,  www.chimerix.com.

CONTACT:Investor Relations: ir@chimerix.com orWill O'ConnorStern Investor Relations Will@sternir.com 212-362-1200

Media:Becky VonsiatskyW2O Group bvonsiatsky@w2ogroup.com 413-478-2003